The final BACE inhibitor in clinical testing for Alzheimer’s disease – Eisai and Biogen’s elenbecestat – has been abandoned. The two companies have decided to discontinue their remaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback